MIST
NASDAQMilestone Pharmaceuticals Inc.
Price$1.23-0.42 (-25.76%)
2026-03-042026-06-05
News · 26 weeks47-89%
2025-12-142026-06-07
Mix2090d
- SEC Filings8(40%)
- Other5(25%)
- Earnings4(20%)
- Insider2(10%)
- Analyst1(5%)
Latest news
25 items- SECSEC Form EFFECT filed by Milestone Pharmaceuticals Inc.EFFECT - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York. A live webcast of the fireside chat will be available to conference participants on May 19th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you
- SECSEC Form S-3 filed by Milestone Pharmaceuticals Inc.S-3 - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate UpdateCARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company makes progress toward broad patient accessAtrial Fibrillation-RVR Phase 3 registration trial initiated: patient enrollment to begin in H2 2026Strong balance sheet of $184.2M provides runway into H2 2027 to fund commercial and operational prioritiesCompany to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of
- SECSEC Form 10-Q filed by Milestone Pharmaceuticals Inc.10-Q - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter ended March 31, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Date:Wednesday, May 13, 2026Conference Time:8:30am ETConference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13760062Webcast link:Click here. Participants can use Guest
- SECSEC Form DEFA14A filed by Milestone Pharmaceuticals Inc.DEFA14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- SECSEC Form DEF 14A filed by Milestone Pharmaceuticals Inc.DEF 14A - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- INSIDERSEC Form 4 filed by Oliveto Joseph4 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- ANALYSTRaymond James initiated coverage on Milestone Pharmaceuticals with a new price targetRaymond James initiated coverage of Milestone Pharmaceuticals with a rating of Strong Buy and set a new price target of $6.00
- PRMilestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVTMONTREAL and CHARLOTTE, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced details on RESET-PSVT, a planned Phase 4, multicenter, prospective, observational registry intended to generate real-world evidence on the use of CARDAMYST™ (etripamil) nasal spray in adults with paroxysmal supraventricular tachycardia (PSVT). "Registry of Etripamil (CARDAMYST™) Studies Evaluating Treatment in Paroxysmal Supraventricular Tachycardia (RESET-PSVT): Study Design," was presented in a poster session at the Preventive Cardiovascular Nurses
- PRMilestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceMONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference to take place April 13 - 16, 2026. A webcast of the presentation will be available on April 13th at 3:45 PM EDT. The webcast will be available to watch here and there will be a replay for approximately 90 days on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference,
- PRMilestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National FormulariesMONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Express Scripts, one of the nation's largest pharmacy benefit managers, has added CARDAMYST™ (etripamil) nasal spray to its commercial national formularies, effective March 27, 2026. This inclusion makes CARDAMYST broadly accessible and affordable for their commercially insured lives across the United States. CARDAMYST is the first and only self-administered nasal spray approved by the U.S. Food and Drug Administration (FDA) for the conversion
- INSIDERSEC Form 3 filed by new insider Sandoval David I.3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- SECMilestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVTFDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE
- SECSEC Form 10-K filed by Milestone Pharmaceuticals Inc.10-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)
- PRMilestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific SessionMONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled "Minimal Blood Pressure Effects of Intranasal Etripamil in Trials for Paroxysmal Supraventricular Tachycardia (PSVT)" will be featured at the 2026 American College of Cardiology Annual Scientific Session (ACC.26), March 28-30th in New Orleans, La. An Expert Theater will also be conducted at ACC.26, providing a deeper look at this new treatment option for adults with symptomatic PSVT. "Although potential h
- PRMilestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti
- PRMilestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care ConferenceMONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place March 2 - 4, 2026, in Boston. A webcast of the presentation will be available on March 3rd at 9:10 AM EST. The webcast will be available to watch live and there will be a replay for approximately 90-days following the presentation on the News & Events section of Milestone's website www.milestonepharma.com. If you are interested in meeting with the Milestone team during the conference, please reach ou
- PRMilestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance OfficerMONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all
- INSIDERAmendment: SEC Form 4 filed by Chief Medical Officer Bharucha David4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by President and CEO Oliveto Joseph4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Commercial Officer Muller Lorenz4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)
MIST FAQ
7 questionsWhat does Milestone Pharmaceuticals Inc. do?
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and...Where does MIST stock trade?
Milestone Pharmaceuticals Inc. (MIST) is listed on NASDAQ.What sector and industry is MIST in?
Milestone Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Milestone Pharmaceuticals Inc. go public?
Milestone Pharmaceuticals Inc. (MIST) completed its IPO in 2019.What are analysts saying about MIST?
Milestone Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $600.00 price target on 2026-04-10. Recent price targets range from $400.00 to $1000.00.What companies are similar to MIST?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare MIST side-by-side with any of them on Quantisnow.How can I track MIST on Quantisnow?
Quantisnow aggregates Milestone Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MIST to receive live email and push alerts on every new disclosure.